ICCC Fundamental Analysis - IMMUCELL CORP

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to ICCC. ICCC was compared to 542 industry peers in the Biotechnology industry. Both the profitability and the financial health of ICCC get a neutral evaluation. Nothing too spectacular is happening here. ICCC is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ICCC had positive earnings in the past year.

In the past year ICCC had a positive cash flow from operations.

ICCC had negative earnings in each of the past 5 years.

In multiple years ICCC reported negative operating cash flow during the last 5 years.

1.2 Ratios

With an excellent Return On Assets value of 3.77%, ICCC belongs to the best of the industry, outperforming 90.96% of the companies in the same industry.

ICCC has a better Return On Equity (5.90%) than 92.07% of its industry peers.

The Return On Invested Capital of ICCC (3.24%) is better than 91.14% of its industry peers.

		Industry Rank	Sector Rank
ROA	3.77%
ROE	5.9%
ROIC	3.24%

ROA(3y)-7.84%

ROA(5y)-5.24%

ROE(3y)-13.05%

ROE(5y)-8.6%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 6.23%, ICCC belongs to the best of the industry, outperforming 91.33% of the companies in the same industry.

ICCC has a better Operating Margin (6.13%) than 90.77% of its industry peers.

ICCC's Gross Margin of 37.44% is fine compared to the rest of the industry. ICCC outperforms 73.62% of its industry peers.

In the last couple of years the Gross Margin of ICCC has declined.

		Industry Rank	Sector Rank
OM	6.13%
PM (TTM)	6.23%
GM	37.44%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-12.67%

GM growth 5Y-9.41%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICCC is destroying value.

ICCC has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ICCC has more shares outstanding

Compared to 1 year ago, ICCC has an improved debt to assets ratio.

2.2 Solvency

An Altman-Z score of 2.75 indicates that ICCC is not a great score, but indicates only limited risk for bankruptcy at the moment.

ICCC has a better Altman-Z score (2.75) than 71.22% of its industry peers.

The Debt to FCF ratio of ICCC is 5.55, which is a neutral value as it means it would take ICCC, 5.55 years of fcf income to pay off all of its debts.

Looking at the Debt to FCF ratio, with a value of 5.55, ICCC belongs to the top of the industry, outperforming 92.25% of the companies in the same industry.

A Debt/Equity ratio of 0.28 indicates that ICCC is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.28, ICCC is doing worse than 70.30% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	5.55
Altman-Z	2.75

ROIC/WACC0.34

WACC9.59%

2.3 Liquidity

A Current Ratio of 3.85 indicates that ICCC has no problem at all paying its short term obligations.

With a Current ratio value of 3.85, ICCC perfoms like the industry average, outperforming 44.46% of the companies in the same industry.

ICCC has a Quick Ratio of 1.99. This is a normal value and indicates that ICCC is financially healthy and should not expect problems in meeting its short term obligations.

ICCC has a Quick ratio of 1.99. This is in the lower half of the industry: ICCC underperforms 73.43% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.85
Quick Ratio	1.99

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 135.85% over the past year.

ICCC shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.74%.

Measured over the past years, ICCC shows a quite strong growth in Revenue. The Revenue has been growing by 14.07% on average per year.

EPS 1Y (TTM)135.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%130%

Revenue 1Y (TTM)21.74%

Revenue growth 3Y11.25%

Revenue growth 5Y14.07%

Sales Q2Q%17.92%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 33.68 indicates a quite expensive valuation of ICCC.

92.07% of the companies in the same industry are more expensive than ICCC, based on the Price/Earnings ratio.

When comparing the Price/Earnings ratio of ICCC to the average of the S&P500 Index (27.13), we can say ICCC is valued slightly more expensively.

		Industry Rank	Sector Rank
PE	33.68
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ICCC is valued cheaper than 94.65% of the companies in the same industry.

93.54% of the companies in the same industry are more expensive than ICCC, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	32.83
EV/EBITDA	13.94

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ICCC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IMMUCELL CORP

NASDAQ:ICCC (8/29/2025, 8:00:02 PM)

After market: 6.28 -0.12 (-1.88%)

6.4

+0.28 (+4.58%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-14 2025-08-14/amc

Earnings (Next)11-11 2025-11-11

Inst Owners18.98%

Inst Owner Change8.18%

Ins Owners22.28%

Ins Owner Change0.29%

Market Cap57.92M

Analysts82.86

Price TargetN/A

Short Float %0.19%

Short Ratio0.49

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	33.68
Fwd PE	N/A
P/S	2.05
P/FCF	32.83
P/OCF	22.87
P/B	1.94
P/tB	1.95
EV/EBITDA	13.94

EPS(TTM)0.19

EY2.97%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.19

FCFY3.05%

OCF(TTM)0.28

OCFY4.37%

SpS3.12

BVpS3.3

TBVpS3.29

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	3.77%
ROE	5.9%
ROCE	4.1%
ROIC	3.24%
ROICexc	3.78%
ROICexgc	3.79%
OM	6.13%
PM (TTM)	6.23%
GM	37.44%
FCFM	6.24%

ROA(3y)-7.84%

ROA(5y)-5.24%

ROE(3y)-13.05%

ROE(5y)-8.6%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-12.67%

GM growth 5Y-9.41%

F-Score8

Asset Turnover0.61

Health

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	5.55
Debt/EBITDA	1.87
Cap/Depr	28.55%
Cap/Sales	2.72%
Interest Coverage	3.52
Cash Conversion	57.22%
Profit Quality	100.13%
Current Ratio	3.85
Quick Ratio	1.99
Altman-Z	2.75

F-Score8

WACC9.59%

ROIC/WACC0.34

Cap/Depr(3y)82.27%

Cap/Depr(5y)105.22%

Cap/Sales(3y)11.34%

Cap/Sales(5y)14.82%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)135.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%130%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)21.74%

Revenue growth 3Y11.25%

Revenue growth 5Y14.07%

Sales Q2Q%17.92%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y144.8%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y118.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y142.29%

OCF growth 3Y-27.78%

OCF growth 5Y9.25%

IMMUCELL CORP (ICCC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens